Skip to content
10-K

Annual Report

MEREO BIOPHARMA GROUP PLC MREO

0001193125-26-115226

← back to feed
Filed
Mar 19, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 18, 2026 798.08M sh
Shares Diluted FY 2025 · Dec 31, 2025 797.12M sh
Shares Diluted FY 2025 · Dec 31, 2024 739.62M sh
Capex FY 2025 · Dec 31, 2025 $20K
Capex FY 2025 · Dec 31, 2024 $0
Operating Cash Flow FY 2025 · Dec 31, 2025 −$30.97M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$32.83M
Cash And Equivalents FY 2025 · Dec 31, 2025 $40.99M
Cash And Equivalents FY 2025 · Dec 31, 2024 $69.8M
Stockholders Equity FY 2025 · Dec 31, 2025 $40.92M
Stockholders Equity FY 2025 · Dec 31, 2024 $60.97M
Stockholders Equity FY 2025 · Dec 31, 2023 $50.54M
Current Liabilities FY 2025 · Dec 31, 2025 $4.3M
Current Liabilities FY 2025 · Dec 31, 2024 $13.85M
Total Liabilities FY 2025 · Dec 31, 2025 $5M
Total Liabilities FY 2025 · Dec 31, 2024 $15.42M
Current Assets FY 2025 · Dec 31, 2025 $45.02M
Current Assets FY 2025 · Dec 31, 2024 $74.76M
Total Assets FY 2025 · Dec 31, 2025 $45.92M
Total Assets FY 2025 · Dec 31, 2024 $76.39M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.05
Eps Diluted FY 2025 · Dec 31, 2024 −$0.06
Eps Basic FY 2025 · Dec 31, 2025 −$0.05
Eps Basic FY 2025 · Dec 31, 2024 −$0.06
Sga Expense FY 2025 · Dec 31, 2025 $23.01M
Sga Expense FY 2025 · Dec 31, 2024 $26.43M
Rd Expense FY 2025 · Dec 31, 2025 $17.77M
Rd Expense FY 2025 · Dec 31, 2024 $20.93M
Net Income FY 2025 · Dec 31, 2025 −$41.88M
Net Income FY 2025 · Dec 31, 2024 −$43.25M
Operating Income FY 2025 · Dec 31, 2025 −$40.11M
Operating Income FY 2025 · Dec 31, 2024 −$47.36M
Revenue FY 2025 · Dec 31, 2025 $500K
Revenue FY 2025 · Dec 31, 2024 $0
Stock Issued FY 2025 · Feb 28, 2025 17.11M sh